View : 769 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author이경자*
dc.contributor.author김승철*
dc.contributor.author문혜성*
dc.contributor.author이레나*
dc.contributor.author주웅*
dc.contributor.author김윤환*
dc.contributor.author이지혜*
dc.contributor.author박경란*
dc.date.accessioned2017-02-15T08:02:57Z-
dc.date.available2017-02-15T08:02:57Z-
dc.date.issued2016*
dc.identifier.issn2234-1900*
dc.identifier.otherOAK-20048*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/234479-
dc.description.abstractPurpose: The purpose of this study is to evaluate the treatment outcomes of adjuvant radiotherapy using vaginal brachytherapy (VB) with a lower dose per fraction and/or external beam radiotherapy (EBRT) following surgery for patients with stage I endometrial carcinoma. Materials and Methods: The subjects were 43 patients with the International Federation of Gynecology and Obstetrics (FIGO) stage I endometrial cancer who underwent adjuvant radiotherapy following surgery between March 2000 and April 2014. Of these, 25 received postoperative VB alone, while 18 received postoperative EBRT to the whole pelvis; 3 of these were treated with EBRT plus VB. The median EBRT dose was 50.0 Gy (45.0-50.4 Gy) and the VB dose was 24 Gy in 6 fractions. Tumor dose was prescribed at a depth of 5 mm from the cylinder surface and delivered twice per week. Results: The median follow-up period for all patients was 57 months (range, 9 to 188 months). Five-year disease-free survival (DFS) and overall survival (OS) for all patients were 92.5% and 95.3%, respectively. Adjuvant radiotherapy was performed according to risk factors and stage IB, grade 3 and lymphovascular invasion were observed more frequently in the EBRT group. Five-year DFS for EBRT and VB alone were 88.1% and 96.0%, respectively (p = 0.42), and 5-year OS for EBRT and VB alone were 94.4% and 96%, respectively (p = 0.38). There was no locoregional recurrence in any patient. Two patients who received EBRT and 1 patient who received VB alone developed distant metastatic disease. Two patients who received EBRT had severe complications, one each of grade 3 gastrointestinal complication and pelvic bone insufficiency fracture. Conclusion: Adjuvant radiotherapy achieved high DFS and OS with acceptable toxicity in stage I endometrial cancer. VB (with a lower dose per fraction) may be a viable option for selected patients with early-stage endometrial cancer following surgery. © 2016. The Korean Society for Radiation Oncology.*
dc.languageEnglish*
dc.publisherDepartment of Radiation Oncology*
dc.subjectAdjuvant radiotherapy*
dc.subjectConformal radiotherapy*
dc.subjectEndometrial cancer*
dc.subjectIntracavity radiotherapy*
dc.titleTreatment outcomes after adjuvant radiotherapy following surgery for patients with stage i endometrial cancer*
dc.typeArticle*
dc.relation.issue4*
dc.relation.volume34*
dc.relation.indexSCOPUS*
dc.relation.startpage265*
dc.relation.lastpage272*
dc.relation.journaltitleRadiation Oncology Journal*
dc.identifier.doi10.3857/roj.2016.01648*
dc.identifier.scopusid2-s2.0-85007578330*
dc.author.googleKim J.*
dc.author.googleLee K.-J.*
dc.author.googlePark K.-R.*
dc.author.googleHa B.*
dc.author.googleKim Y.-J.*
dc.author.googleJung W.*
dc.author.googleLee R.*
dc.author.googleKim S.C.*
dc.author.googleMoon H.S.*
dc.author.googleJu W.*
dc.author.googleKim Y.H.*
dc.author.googleLee J.*
dc.contributor.scopusid이경자(55540780700)*
dc.contributor.scopusid김승철(35264000100)*
dc.contributor.scopusid문혜성(14319143700)*
dc.contributor.scopusid이레나(8694612100)*
dc.contributor.scopusid주웅(8873659700)*
dc.contributor.scopusid김윤환(55763947200)*
dc.contributor.scopusid이지혜(57203145157;56216251300)*
dc.contributor.scopusid박경란(14040340300;57203047823;57207108839;57308917900)*
dc.date.modifydate20240419140415*
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE